Ifrah Financial Services, Inc. Halozyme Therapeutics, Inc. Transaction History

Ifrah Financial Services, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$33.32 - $42.1 $12,361 - $15,619	-371 Reduced 5.77%	6,060 $223,000
Q3 2023 Nov 06, 2023	SELL	$36.46 - $44.03 $2,406 - $2,905	-66 Reduced 1.02%	6,431 $245,000
Q2 2023 Aug 01, 2023	SELL	$30.28 - $38.74 $2,725 - $3,486	-90 Reduced 1.37%	6,497 $234,000
Q1 2023 May 04, 2023	SELL	$32.86 - $55.7 $5,389 - $9,134	-164 Reduced 2.43%	6,587 $251,000
Q4 2022 Feb 06, 2023	SELL	$40.06 - $59.44 $10,856 - $16,108	-271 Reduced 3.86%	6,751 $384,000
Q3 2022 Nov 07, 2022	SELL	$38.53 - $51.78 $1,001 - $1,346	-26 Reduced 0.37%	7,022 $278,000
Q2 2022 Aug 05, 2022	BUY	$37.35 - $48.3 $263,242 - $340,418	7,048 New	7,048 $310,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Ifrah Financial Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Ifrah Financial Services, Inc. with notifications on news.